Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms (MPNPH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02580903|
Recruitment Status : Recruiting
First Posted : October 20, 2015
Last Update Posted : October 20, 2015
This is an observational prospective study aiming to clarify the prevalence of pulmonary hypertension in patients with Myeloproliferative Neoplasms and their prognosis.
All patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. All will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the European Cardiology Association.
All patients will be followed up for a total of five years to identify prognosis.
|Condition or disease||Intervention/treatment|
|Myeloproliferative Disorders Pulmonary Hypertension||Radiation: Radiology|
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||Pulmonary Hypertension in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms; an Observational Prospective Study|
|Study Start Date :||February 2015|
|Estimated Primary Completion Date :||February 2016|
|Estimated Study Completion Date :||February 2021|
- Radiation: Radiology
Only a small subsample will require CT and right heart catherisation
- Prevalence of pulmonary hypertension at initial presentation and first echo [ Time Frame: Initial recruitment ]
- Mortality [ Time Frame: 1 and 5 years ]
- Incidence of pulmonary hypertension while under follow-up [ Time Frame: 5 years ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02580903
|Contact: Mette Brabrand, MDfirstname.lastname@example.org|
|Contact: Hanne Vestergaard, MD PhDemail@example.com|
|Odense University Hospital||Recruiting|
|Odense, Denmark, 5000|
|Contact: Mette Brabrand, MD +4566113333 firstname.lastname@example.org|
|Principal Investigator:||Mette Brabrand, MD||Odense University Hospital|